Securities & Exchange Commission v. Sabrdaran

252 F. Supp. 3d 866, 2017 WL 2081339, 2017 U.S. Dist. LEXIS 73850
District Court, N.D. California·Decided May 15, 2017·No. Case No. 14-cv-04825-JSC·Published·Cited by 5 cases

Opinion

ORDER RE POST-TRIAL AND REMEDY MOTIONS

Re: Dkt. Nos. 170, 175

JACQUELINE SCOTT CORLEY, United States Magistrate Judge

Plaintiff Securities and Exchange Commission (“SEC”) charge that Defendants Sasan Sabrdaran and Farhang Afsarpour engaged in insider trading in violation of the antifraud provisions of the Securities Exchange Act of 1934. Following a three-week trial, the jury returned a verdict in the SEC’s favor. Now pending before the Court are Defendants’ joint motion for judgment as a matter of law, or in the alternative, a new trial and the SEC’s post-trial remedies motion. (Dkt. Nos. 170, 175.1) Having had the benefit of oral argument on March 23, 2017, and having carefully considered the parties’ written submissions, including their post-oral argument submissions, the Court DENIES Defendants’ motion and GRANTS IN PART the SEC’s remedies motion as set forth below.

BACKGROUND

The SEC alleged that Defendants engaged in insider trading when Dr. Sa-brdaran, an employee of pharmaceutical company InterMune, Inc., tipped his longtime friend Afsarpour to material, nonpublic information about the progress through the European regulatory approval process of Esbriet, one of InterMune’s products, and Afsarpour then acted on that tip by engaging in transactions in connection with InterMune securities. After receiving the nonpublic information about Esbriet’s EU approval on the eve of the public announcement in December 2010, Afsarpour — who lives in the UK — placed certain online financial bets on the price changes in InterMune stock and options; specifically, he placed spread bets through a London-based company called IG Index and also bought InterMune stock via his stockbroker in New York. Afsarpour urged others to invest in InterMune as well, some of whom did.

Dr. Sabrdaran served on the InterMune team seeking marketing approval for Es-briet from the European Medicines Agency. Afsarpour is a close personal friend of Dr. Sabrdaran, and they communicated by phone, email, Faeebook and other means frequently to discuss developments in their lives, philosophy, and other personal issues. They also tried to visit each other when one of them was present in the other’s country. Afsarpour contended that he started placing spread bets on InterMune stock in November 2010 based on his own [874] research about the company. He insisted-that, based on publicly available information, he believed that InterMune would receive approval from the European Medicines Agency during the first quarter of 2011 to market and sell Esbriet in the European Union, and that this approval would be announced during the first quarter of 2011. He maintained that he did not receive any material nonpublic information from Dr. Sabrdaran or anyone else regarding InterMune.

' Early in the case, the Court granted in' part and denied in part Defendants’ motions to. dismiss and denied their motion to strike portions of the initial complaint. (Dkt. No. 36.) Defendants’argued, among other things,- that the transactions at issue involve spread bets, which are not “securities” for the purposes of a Section 10(b) and Rule 10(b)-5 violation. The Court concluded that the SEC, with minimal amendment, could plausibly allege that Afsarp-our’s spread bets were “in connection* with” securities by alleging.that IG Index had hedged his spread bets, which the SEC amended to do. After discovery, the Court denied the SEC’s motion for partial, summary judgment on the same issue, holding that to establish a securities violation under Section 10(b) and Rule 10(b)-5, the SEC need not necessarily.prove that Afsarpour subjectively knew that his fraudulent activity was “in connection with” the purchase or sale of a security, but that a reasonable trier of fact might not find that Afsarpour’s spread bets necessarily, met that test.

Trial began on October 17, 2016. The parties agreed that Defendants shared a. very close friendship; beyond that, the SEC and Defendants presented very different accounts. The SEC .elicited testimony and proffered documentary evidence connecting the confidential and public announcements about Esbriet, communications between Defendants, and Afsarpour’s trading activity. For example, there was testimony that Dr.’ Sabrdaran communicated with Afsarpour shortly after receiving a confidential, internal InterMune email stating that the European Medicines Agency had given the green light for Es-brief> — the “As Good As It Gets” email. There was testimony that Afsarpour executed very few trades on InterMuné until mid-December 2010, the eve of Esbriet’s imminent approval announcement; that the days leading up to the announcement he encouraged friends to invest heavily in InterMune; and that the day before the public announcement he invested more heavily than ever before, in more highly leveraged transactions than ever before, using credit'cards to fund , his bets, which he had never done-before,- The SEC entered emails into the record in which, the day before the public announcement, Af-sarpour wrote to friends telling them to get their money in that day before .it was too late.

In the SEC’s case-in-chief, the jury heard from Dan Welch, InterMune’s CEO, who described the company’s business and confidentiality policies’ generally. Steven Porter and Marianne Porter, doctors and InterMune executives, repeated .Inter-Mune’s confidentiality policies, explained the process of regulatory review before the European Medicines Agency generally and for Esbriet’ in particular, described Dr. Sabrdaran’s role in the group that worked on Esbriet’s drug safety, and discussed who. knew about its approval before the news became public. Dr. Spencer Hudson, another doctor on the Esbriet team, also testified about what he and the other members of the team knew as they shepherded the drug through the approval process. They testified that InterMune learned on December 10, 2010 that .the European Medicines Agency would announce Esbriet’s approval on December 17; 2010.

[875] Apart from InterMune employees, two employees from IG Index testified. Bridget Messer, a financial services attorney who is the company’s chief commercial officer, discussed the “spread bets” that IG Index offers, explaining how the company often hedges its customers’ spread bets, how the contracts each customer — including Af-sarpour — signs in advance of placing any spread bets inform them that IG Index might hedge, and how IG Index’s internal compliance department investigated trades in InterMune in December 2010 and froze Afsarpour’s account.

Free access — add to your briefcase to read the full text and ask questions with AI

Securities & Exchange Commission v. Sabrdaran, 252 F. Supp. 3d 866, 2017 WL 2081339, 2017 U.S. Dist. LEXIS 73850 (N.D. Cal. 2017).

252 F. Supp. 3d 866 (Securities & Exchange Commission v. Sabrdaran) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related